Onconova Therapeutics, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011
Total Revenue 4,753 46,190 1,487
Cost of Revenue - - -
Gross Profit 4,753 46,190 1,487
Operating Expenses
Research and Development 50,182 52,762 22,624
Sales, General and Admin. 16,793 15,707 6,436
Non-Recurring Items - - -
Other - - -
Operating Income (62,222) (22,279) (27,573)
Income From Continuing Operations
Add'l Income/Expense Items 105 975 1,298
Earnings Before Interest and Tax (62,117) (21,304) (26,275)
Interest Expense 4 8,608 19
Earnings Before Tax (62,121) (29,912) (26,294)
Income Tax 435 - -
Minority Interest (13) - -
Equity Earnings Unconsolidated Subsidiary - - -
Net Income Cont. Operations (62,543) (29,912) (26,294)
Non Recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect of Accounting Changes - - -
Other Items - - -
Net Income (62,543) (29,912) (26,294)
Preferred Stock and Other Adjustments (2,320) (3,953) (4,020)
Net Income Applicable to Common Shareholders (64,863) (33,865) (30,314)